NEW YORK – After announcing a collaboration with Intermountain Health spinout Culmination Bio earlier this week, Cofactor Genomics is “moving aggressively” to advance its OncoPrism test for predicting whether patients with a range of cancers are likely to benefit from immunotherapy.